Five of these genes, including CDK1, Pituitary Tumour-Transforming 1 (PTTG1), cyclin B2 (CCNB2), cyclin E1 (CCNE1) and S-phase kinase-associated protein 2 (SKP2), were chosen to test whether these active genes in ACC may be inhibited following miR-7 therapy. The gene discussed is CCNE1; the disease is adrenal cortex carcinoma.